Quote: ‘The Hipra vaccine has the advantages of being developed using existing and well-known technology’

THE new Covid-19 vaccine clinical trials in Spain has registered 30 volunteers with some undergoing injections in a bid for the country to find a successful inoculation against the virus.

Girona based Hipra Laboratories is developing a formula using two different Coronavirus strains, to increase immunity including the more contagious and aggressive types.

First doses were given at Girona’s Josep Trueta Hospital and Barcelona’s Hospital Clínic, according to Dr Marga Nadal, head of the Girona Biomedical Research Institute (IDIBGI) and Dr Àlex Soriano, head of the infectious diseases unit at Hospital Clínic.

The vaccine is being tested on healthy men and women aged between 18-39, who have not had Covid-19 and not prior vaccinated.

Authorised by the Spanish Medicines and Healthcare Products Agency (AEMPS).

Dr Lorna Leal, specialist at the Clínic’s infectious diseases unit and a member of the AIDS and HIV Infection Group at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) in Barcelona, is heading the research project.

The clinical trials will take a year to complete, for those vaccinated with the Pfizer/Hipra vaccine, with Hipra reportedly working on the basis its formula will be used as an annual booster.

The Hipra vaccine is a PHH-1V formula, similar to the Novavax and the Sanofi/GSK, being evaluated by the European Medicines Agency (EMA).

“The Hipra vaccine has the advantages of being developed using existing and well-known technology,” said Dr Leal.